Research News
View articles by month and year
-
Combination of Arimidex and Faslodex Better Than Arimidex Alone to Treat Metastatic Breast Cancer
A study has found that postmenopausal women diagnosed with hormone-receptor-positive metastatic breast cancer and treated with a combination of Arimidex and Faslodex as the first treatment for metastatic disease lived about 6 months longer than women treated only with Arimidex.
-
Arimidex-Faslodex Combo Improves Survival in Metastatic Breast Cancer
A study has found that postmenopausal women diagnosed with hormone-receptor-positive metastatic breast cancer and treated with a combination of Arimidex and Faslodex as the first treatment for metastatic disease lived 6 months longer than women treated only with Arimidex.
-
Femara Offers More Benefits Than Tamoxifen After Breast Cancer Surgery
New results boost evidence that postmenopausal women get more benefits from 5 years of Femara compared to 5 years of tamoxifen after surgery for early-stage, hormone-receptor-positive breast cancer.
-
Hormonal Therapy Before Surgery May Be Good Treatment for Postmenopausal Women with Hormone-Receptor-Positive, Locally Advanced Disease
Research suggests that hormonal therapy before surgery may be a good alternative to chemotherapy before surgery for postmenopausal women diagnosed with hormone-receptor-positive breast cancer.
-
Most Women with Early-Stage Breast Cancer Benefit from Treatments After Surgery
Research suggests that that most women diagnosed with early-stage breast cancer are likely to benefit from chemotherapy, hormonal therapy, and/or targeted therapy after surgery.
-
Is Switching Hormonal Therapies Better Than Taking Only One?
Research suggests that taking tamoxifen for 2 to 3 years and then switching to an aromatase inhibitor might be better than taking only tamoxifen or only an aromatase inhibitor for 5 years to reduce recurrence risk and improve overall survival.
-
Zometa Plus Hormonal Therapy Reduces Recurrence Risk
A study has found that Zometa and hormonal therapy after surgery could reduce the risk of the cancer coming back in premenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer better than hormonal therapy alone.
-
Aromatase Inhibitors Increase Risk of Heart Problems
Women diagnosed with early-stage, hormone-receptor-positive breast cancer who got 5 years of an aromatase inhibitor seem to be more likely to have heart problems compared to women who got 5 years of tamoxifen.
-
Radiation, Tamoxifen After DCIS Surgery Reduces Recurrence Risk
Research shows that radiation therapy and hormonal therapy after surgery for DCIS reduces the risk of being diagnosed with either another DCIS or invasive breast cancer in the future.
-
Arimidex Still Better Than Tamoxifen After Surgery to Reduce Recurrence Risk
After 10 years of follow-up, research shows that 5 years of Arimidex is better at reducing the risk of hormone-receptor-positive breast cancer recurrence than 5 years of tamoxifen.
